Pharmaceutical industry – Page 29
-
PodcastGabapentin
Louise Crane documents the rise and fall of Gabapentin – from ‘wonder drug’ to illicit substance in just 50 years
-
BusinessTroubled Theranos abandons clinical testing
Seeking to salvage some value, once-admired blood analysis firm lays off 40% of staff
-
BusinessNovartis consolidates research sites
Company will close research sites in China and Switzerland, and relocate another from Singapore to US
-
BusinessIndia’s Intas bags UK and Irish generics
Teva sheds former Actavis business to satisfy competition requirements of its Allergan generics takeover
-
BusinessPfizer to sell Hospira Infusion Systems to ICU Medical
$1bn deal brings together medical device units, as Pfizer focuses on Hospira’s biosimilars and generics
-
BusinessLilly to buy Boehringer’s pet vaccines
Deal strengthens Lilly’s animal medicine division following recent acquisition
-
BusinessNovo Nordisk to axe 1000 jobs
Diabetes specialist is cutting costs in the face of increased competition
-
OpinionBooster shot
Zika and Ebola have highlighted the pharmaceutical industry’s ability to respond to critical needs
-
BusinessPfizer scraps plans to split
Previously separated ‘innovative’ and ‘value’ business segments will remain autonomous under Pfizer umbrella
-
NewsPharma giants commit to tackling antimicrobial resistance
Plan to tackle superbugs includes changes to manufacturing and sales incentives
-
BusinessAcquisition spree moves Allergan towards innovative drugs
Company acquires five companies in six weeks across three disease areas
-
BusinessSanofi sues Merck & Co over biosimilars
Merck challenges insulin patents, but Sanofi claims infringement
-
OpinionSlimmer synthesis
Atom economy is a noble aim, but there are other routes to efficient molecule making
-
BusinessJ&J to buy Abbott Medical Optics
Deal adds laser surgery and cataract lens replacements to J&J’s eyecare business
-
BusinessDanaher boosts diagnostics with Cepheid buyout
$4bn deal strengthens Danaher’s life sciences portfolio
-
BusinessFDA’s first Duchenne drug approval reveals schism
Oligonucleotide drug reaches market amid pressure from patient families and strife over ‘patient-focused drug development’ at the regulator
-
BusinessBrexit could push Japanese pharma out of the UK
Warnings that Japanese R&D investment in the UK is endangered by plans to leave the EU
-
BusinessHealthcare firms invest in Crispr gene editing technology
Crispr licence agreements open up opportunities in drug discovery
-
BusinessNovartis reshuffle puts 120 staff at risk
Commitment to gene and cell therapy treatments emphasised as unit broken up amid pharmaceutical division refocus
-
OpinionDon’t fear the Crispr
Does simple gene-editing mean the end of traditional medicinal chemistry? Probably not